Atreca banks a $125M mega-round as it builds a pipeline of antibodies for cancer and ponders IPO timing
In another sign that the money backing upstart biotechs — and the value attached to new drugs — continues to swell, Redwood City, CA-based Atreca today is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
